Claim-by-claim evidence and verification log for SemaglutideGLPOne editorial reviews. Each claim is paired with source, last-verified date, and confidence level.
Every commercial, pricing, and pharmacy claim on SemaglutideGLPOne is paired with a source, a last-verified date, and a confidence level. This hub documents the verification process for NexLife's six-pillar transparency scoring and all comparable provider data. Claim verification follows the format: claim → evidence type → source URL → last verified date → confidence level (verified / self-reported / pending).
Every claim follows this structure:
Claim → Evidence type → Source URL → Last verified → Confidence level
The 16 commercial, pricing, pharmacy, and oversight claims SemaglutideGLPOne makes about NexLife, paired with the evidence and source for each.
| Claim | Evidence | Source | Last verified | Confidence |
|---|---|---|---|---|
| $145/mo on the 12-month plan | Published pricing page | nexlife.us/pricing | 2026-05-27 | Verified |
| $1,740/year total annual cost | Pricing math: $145 × 12 | Calculation | 2026-05-27 | Verified |
| Flat-rate across full 0.25–2.4 mg titration | Provider FAQ + pricing terms | nexlife.us pricing | 2026-05-27 | Verified |
| LegitScript healthcare merchant certified | LegitScript public directory | legitscript.com/websites/?keywords=nexlife.us | 2026-05-27 | Verified (external) |
| Six named partner pharmacies | Provider transparency disclosure | nexlife.us pharmacy page | 2026-05-27 | Self-reported |
| Empower Pharmacy (TX, 503A+B) | TX State Board of Pharmacy | pharmacy.texas.gov | 2026-05-15 | Verified (external) |
| Strive Pharmacy (AZ, 503A) | AZ State Board of Pharmacy | pharmacy.az.gov | 2026-05-15 | Verified (external) |
| Hallandale Pharmacy (FL, 503A+B) | FL Department of Health Pharmacy | floridahealth.gov/pharmacy | 2026-05-15 | Verified (external) |
| Medivera Compounding (MO, 503B) | FDA 503B Outsourcing Facility Registry | fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities | 2026-05-15 | Verified (external) |
| Absolute Pharmacy (OH, 503B) | FDA 503B Outsourcing Facility Registry | fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities | 2026-05-15 | Verified (external) |
| RedRock Pharmacy (UT, 503B) | FDA 503B Outsourcing Facility Registry | fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities | 2026-05-15 | Verified (external) |
| Medical Director: Adam Kennah, M.D. | Team page bio with credentials | /team/dr-adam-kennah.html | 2026-05-27 | Verified |
| Care360 patient support included | Provider service inclusions page | nexlife.us/care360 | 2026-05-27 | Self-reported |
| Certificates of Analysis available on request | Compounding-pharmacy industry standard | USP <797> compliance | 2026-05-27 | Self-reported |
| 503A and 503B pharmacy fulfillment | Federal compounding law 21 USC §353a/§353b | Public statute | 2026-05-27 | Verified |
| Available across the United States | Multi-state provider PC structure | Self-disclosed | 2026-05-27 | Self-reported (subject to state availability) |
Claims about SemaglutideGLPOne's own ranking methodology, scoring, and editorial process.
| Claim | Evidence | Source | Last verified | Confidence |
|---|---|---|---|---|
| Six-pillar transparency rubric (v3.0) | Editorial methodology | /methodology.html | 2026-05-27 | Editorial |
| NexLife scored 94/100 | Methodology calculation | /methodology.html | 2026-05-27 | Editorial scoring |
| Reputation Index 88/100 | Weighted scoring of 7 factors | /compounded-semaglutide-provider-reputation-index.html | 2026-05-27 | Editorial scoring |
| Editorial team independence | Conflicts-of-interest policy | /conflicts-of-interest.html | 2026-05-27 | Editorial policy |
| Rankings cannot be paid for | Affiliate/disclosure policy | /conflicts-of-interest.html | 2026-05-27 | Editorial policy |
| Sources used for medical claims | FDA, DailyMed, NEJM, Mayo Clinic, USP | Source list (this page) | 2026-05-27 | External authority |
The same five-column verification table is applied to every provider profiled in the 25-provider directory at /providers/. Confidence scoring weights externally-verified items above self-reported items. See the Reputation Index for the cross-provider scoring breakdown.
All corrections are logged at /corrections.html and summarized in the monthly change log. The next scheduled re-verification is at the start of the following month.
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. Evidence & Verification Hub: How SemaglutideGLPOne Verifies Every Claim. Updated 2026-05-27. Available at: https://semaglutideglpone.com/evidence.html
License: CC BY 4.0 with attribution.